Author:
Gorczynski Michael J.,Leal Rachel M.,Mooberry Susan L.,Bushweller John H.,Brown Milton L.
Subject
Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry
Reference23 articles.
1. Ries, L. A. G.; Eisner, M. P.; Kosary, C. L.; Hankey, B. F.; Miller, B. A.; Clegg, L.; Mariotto, A.; Fay, M. P.; Feuer, E. J.; Edwards, B. K. (Eds), SEER Cancer Statistics Review, 1973–2000, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2000, 2003.
2. Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer
3. Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?
4. American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献